ARGatroban Injection in patients with acute ischemic Stroke "ARGIS-1"

Completed

Phase N/A Results

Summary of Purpose

To determine the safety of Argatroban injection and its optimum effective doses in patients with acute ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 28 July 2008.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Texas Biotechnology Corporation, Mitsubishi-Tokyo Pharmaceuticals

Trial Design

Randomized, blinded, placebo-controlled, three-treatment-arm trial with an anticipated enrollment of 180 patients at 55 centers.

Contacts

Not available